Flexion Therapeutics (NASDAQ: FLXN) reported top-line results from the first of two pivotal clinical trials of its lead drug candidate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Needham & Company Cuts Price Target on Flexion Therapeutics (FLXN) Following Top-Line FX006 Data September 9, 2015 7:41 AM Ampio Pharma (AMPE) Mentioned Cautiously in Connection with Flexion's Trial FailureSeptember 8, 2015 5:26 PM Flexion Therapeutics Reports Top-Line Data From Pivotal Phase 2b Clinical Trial for FX006September 8, 2015 4:01 PM Flexion Therapeutics Reports Top-Line Data From Pivotal Phase 2b Clinical Trial for FX006September 8, 2015 4:01 PM